Associations Between Model-Predicted Rivaroxaban Ex Characteristics and Efficacy and Safety Outcomes in Pa Fibrillation

Journal of Thrombosis and Thrombolysis

50, 20-29

DOI: 10.1007/s11239-020-02077-9

Citation Report

#	Article	IF	Citations
1	2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thrombosis and Haemostasis, 2021, 121, 1008-1020.	4.6	206
2	How to Handle the Delayed or Missed Dose of Rivaroxaban in Patients With Non-Valvular Atrial Fibrillation: Model-Informed Remedial Dosing. Expert Review of Clinical Pharmacology, 2021, 14, 1153-1163.	3.6	11
3	Medications That Interact With Direct-Acting Oral Anticoagulant Exposure. Netherlands Heart Journal, 2021, 29, 417-418.	2.6	0
4	Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study. TH Open, 2022, 06, e10-e17.	1.8	6
5	Developing LC–MS/MS Methods to Quantify Rivaroxabanin Human Plasma and Urine: Application to Therapeutic Drug Monitoring. Biomedical Chromatography, 2022, 36, e5306.	1.8	3
6	A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation. Frontiers in Pharmacology, 2022, 13, 814724.	5.3	10
7	Evaluating Pharmacokinetic Drug–Drug Interactions of Direct Oral Anticoagulants in Patients With Renal Dysfunction. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 189-202.	4.8	6
8	Physiologically-Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions of Dabigatran Etexilate and Rivaroxaban in the Chinese Older Adults. European Journal of Pharmaceutical Sciences, 2023, 182, 106376.	5.8	12
9	Clinical Significance of the Rivaroxaban-Dronedarone Interaction: Insights From Physiologically Based Pharmacokinetic Modelling. European Heart Journal Open, 2023, 3, oead004.	3.6	5
10	Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban. Pharmaceutics, 2023, 15, 588.	7.5	25
11	Poor Correlation of Rivaroxaban Concentration With the Routine Coagulation Screening Test in Chinese Patients With Atrial Fibrillation. Journal of Clinical Pharmacy and Therapeutics, 2023, .	1.0	1
12	An Extension of Biorelevant Fed-State Dissolution Tests to Clinical Pharmacokinetics – A Study on Gastrointestinal Factors Influencing Rivaroxaban Exposure and Efficacy in Atrial Fibrillation Patients. International Journal of Pharmaceutics, 2024, 649, 123626.	6.1	8
13	Efficacy and Safety of Different Dosing Regimens of Rivaroxaban in Patients With Atrial Fibrillation for Stroke Prevention: A Systematic Review and Meta-Analysis. Cureus, 2024, 16, e51541.	1.3	3
14	Assessing the Safety and Efficacy of Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation: A Systemic Review and Meta-Analysis. Cureus, 2024, 16, e54252.	1.3	0
15	Direct Oral Anticoagulants in Older and Frail Patients With Atrial Fibrillation: A Decade of Experience. Drugs and Aging, 2024, 41, 1-16.	4.9	18
16	Usual On-Therapy Ranges of Drug Concentrations in Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2025, 125, 563-573.	4.6	12
17	Edoxaban for Atrial Fibrillation in Patients With Atherosclerotic Disease in Daily Clinical Practice. Journal of Thrombosis and Thrombolysis, 2026, 59, 1362-1374.	2.2	1